Incremental effects of endocrine and metabolic biomarkers and abdominal obesity on cardiovascular mortality prediction

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Schneider, J ̈rn ^a,b   Wallaschofski, Henri ^a   Völzke, Henry ^a   Markus, Marcello Ricardo Paulista ^a   Doerr, Marcus ^a   Felix, Stephan B ^a   Nauck, Matthias ^a   Friedrich, Nele ^a  

^a UNIVERSITY OF GREIFSWALD   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANTIHYPERTENSIVE AGENT; C REACTIVE PROTEIN; CREATININE; FIBRINOGEN; HEMOGLOBIN A1C; SOMATOMEDIN C; TESTOSTERONE; THYROTROPIN; BIOLOGICAL MARKER; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ABDOMINAL OBESITY; ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE MARKER; ENDOCRINE DISEASE; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MICROALBUMINURIA; MORTALITY; POPULATION RESEARCH; PREDICTION; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; WAIST HIP RATIO; AGED; GERMANY; LONGITUDINAL STUDY; METABOLISM; MIDDLE AGED; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; COHORT STUDIES; FEMALE; GERMANY; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN-LIKE GROWTH FACTOR I; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; OBESITY, ABDOMINAL; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; YOUNG ADULT;

EID: 84858419843     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0033084     Document Type: Article

References (39)

1. Anderson KM, Wilson PW, Odell PM, Kannel WB, (1991) An updated coronary risk profile. A statement for health professionals. Circulation pp. 356-362.
2. Expert Panel on DetectionEvaluationTreatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) (2001) Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP). JAMA pp. 2486-2497.
3. Assmann G, Cullen P, Schulte H, (1998) The Munster Heart Study (PROCAM). Results of follow-up at 8 years. Eur Heart J 19 (Suppl A): A2-11.
4. Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, et al. (2003) Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart pp. 987-1003.
5. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, et al. (1998) Prediction of coronary heart disease using risk factor categories. Circulation pp. 1837-1847.
6. Blankenberg S, McQueen MJ, Smieja M, Pogue J, Balion C, et al. (2006) Comparative impact of multiple biomarkers and N-Terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation pp. 201-208.
7. Blankenberg S, Zeller T, Saarela O, Havulinna AS, Kee F, et al. (2010) Contribution of 30 biomarkers to 10-year cardiovascular risk estimation in 2 population cohorts: the MONICA, risk, genetics, archiving, and monograph (MORGAM) biomarker project. Circulation pp. 2388-2397.
8. Melander O, Newton-Cheh C, Almgren P, Hedblad B, Berglund G, et al. (2009) Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. JAMA pp. 49-57.
9. Ridker PM, Buring JE, Rifai N, Cook NR, (2007) Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA pp. 611-619.
10. Wang TJ, Gona P, Larson MG, Tofler GH, Levy D, et al. (2006) Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med pp. 2631-2639.
11. Zethelius B, Berglund L, Sundstrom J, Ingelsson E, Basu S, et al. (2008) Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N Engl J Med pp. 2107-2116.
12. Ochs N, Auer R, Bauer DC, Nanchen D, Gussekloo J, et al. (2008) Meta-analysis: subclinical thyroid dysfunction and the risk for coronary heart disease and mortality. Ann Intern Med pp. 832-845.
13. Laughlin GA, Barrett-Connor E, Criqui MH, Kritz-Silverstein D, (2004) The prospective association of serum insulin-like growth factor I (IGF-I) and IGF-binding protein-1 levels with all cause and cardiovascular disease mortality in older adults: the Rancho Bernardo Study. J Clin Endocrinol Metab pp. 114-120.
14. Friedrich N, Haring R, Nauck M, Lüdemann J, Rosskopf D, et al. (2009) Mortality and serum insulin-like growth factor (IGF)-I and IGF binding protein 3 concentrations. J Clin Endocrinol Metab pp. 1732-1739.
15. Saydah S, Graubard B, Ballard-Barbash R, Berrigan D, (2007) Insulin-like growth factors and subsequent risk of mortality in the United States. Am J Epidemiol pp. 518-526.
16. Haring R, Völzke H, Steveling A, Krebs A, Felix SB, et al. (2010) Low serum testosterone levels are associated with increased risk of mortality in a population-based cohort of men aged 20-79. Eur Heart J pp. 1494-1501.
17. Shores MM, Matsumoto AM, Sloan KL, Kivlahan DR, (2006) Low serum testosterone and mortality in male veterans. Arch Intern Med pp. 1660-1665.
18. Laughlin GA, Barrett-Connor E, Bergstrom J, (2008) Low serum testosterone and mortality in older men. J Clin Endocrinol Metab pp. 68-75.
19. Adams RJ, Appleton SL, Hill CL, Wilson DH, Taylor AW, et al. (2009) Independent association of HbA(1c) and incident cardiovascular disease in people without diabetes. Obesity pp. 559-563.
20. Gerstein HC, Swedberg K, Carlsson J, McMurray JJ, Michelson EL, et al. (2008) The hemoglobin A1c level as a progressive risk factor for cardiovascular death, hospitalization for heart failure, or death in patients with chronic heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Arch Intern Med pp. 1699-1704.
21. Khaw KT, Wareham N, Luben R, Bingham S, Oakes S, et al. (2001) Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of european prospective investigation of cancer and nutrition (EPIC-Norfolk). BMJ pp. 15-18.
22. Chonchol M, Katz R, Fried LF, Sarnak MJ, Siscovick DS, et al. (2010) Glycosylated hemoglobin and the risk of death and cardiovascular mortality in the elderly. Nutr Metab Cardiovasc Dis pp. 15-21.
23. Gelber RP, Gaziano JM, Orav EJ, Manson JE, Buring JE, et al. (2008) Measures of obesity and cardiovascular risk among men and women. J Am Coll Cardiol 2008; 52: 605-615.
24. Schneider HJ, Friedrich N, Klotsche J, Pieper L, Nauck M, et al. (2010) The predictive value of different measures of obesity for incident cardiovascular events and mortality. J Clin Endocrinol Metab pp. 1777-1785.
25. John U, Greiner B, Hensel E, Ludemann J, Piek M, et al. (2001) Study of Health In Pomerania (SHIP): a health examination survey in an east German region: objectives and design. Soz Praventivmed pp. 186-194.
26. Völzke H, Alte D, Schmidt CO, Radke D, Lorbeer R, et al. (2011) Cohort Profile: The Study of Health in Pomerania. Int J Epidemiol pp. 294-307.
27. Völzke H, Alte D, Kohlmann T, Ludemann J, Nauck M, et al. (2005) Reference intervals of serum thyroid function tests in a previously iodine-deficient area. Thyroid pp. 279-285.
28. Pencina MJ, D'Agostino RB, (2004) Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med pp. 2109-2123.
29. Newson RB, (2010) Comparing the predictive power of survival models using Harrell's C or Somers' D. The Stata Journal pp. 339-358.
30. Haring R, Volzke H, Felix SB, Schipf S, Dorr M, et al. (2009) Prediction of metabolic syndrome by low serum testosterone levels in men: Results from the Study of Health in Pomerania. Diabetes pp. 2027-2031.
31. Schneider HJ, Sievers C, Klotsche J, Bohler S, Pittrow D, et al. (200) Prevalence of low male testosterone levels in primary care in Germany: cross-sectional results from the DETECT study. Clin Endocrinol pp. 446-454.
32. Volzke H, Schwahn C, Wallaschofski H, Doerr M, (2007) Review: The association of thyroid dysfunction with all-cause and circulatory mortality: is there a causal relationship? J Clin Endocrinol Metab pp. 2421-2429.
33. Rajpathak SN, Gunter MJ, Wylie-Rosett J, Ho GY, Kaplan RC, et al. (200) The role of insulin-like growth factor-I and its binding proteins in glucose homeostasis and type 2 diabetes. Diabetes Metab Res Rev pp. 3-12.
34. Juul A, (2003) Serum levels of insulin-like growth factor I and its binding proteins in health and disease. Growth Horm IGF Res pp. 113-170.
35. Empen K, Lorbeer R, Völzke H, Robinson DM, Friedrich N, et al. (2010) Association of serum insulin-like growth factor I with endothelial function: Results from the population-based Study of Health in Pomerania (SHIP). Eur J Endocrinol pp. 617-623.
36. Schneider HJ, Klotsche J, Silber S, Stalla GK, Wittchen HU, (2011) Measuring abdominal obesity: effects of height on distribution of cardiometabolic risk factors risk using waist circumference and waist-to-height ratio. Diabetes Care 34: e7.
37. Flegal KM, Graubard BI, Williamson DF, Gail MH, (2007) Cause-specific excess deaths associated with underweight, overweight, and obesity. JAMA pp. 2028-2037.
38. Romero-Corral A, Montori VM, Somers VK, Korinek J, Thomas RJ, et al. (2006) Association of bodyweight with total mortality and with cardiovascular events in coronary artery disease: a systematic review of cohort studies. Lancet pp. 666-678.
39. Gruberg L, Weissman NJ, Waksman R, Fuchs S, Deible R, et al. (2002) The impact of obesity on the short-term and long-term outcomes after percutaneous coronary intervention: the obesity paradox? J Am Coll Cardiol pp. 578-584.